Mark Dawson is a clinician-scientist whose research interest is studying epigenetic regulation in normal and malignant haematopoiesis. He is the head of the Cancer Epigenetics Laboratory and a Haematologist in the Department of Haematology at the Peter MacCallum Cancer Centre. After completing his clinical training in Melbourne, Australia he was awarded the prestigious General Sir John Monash Fellowship and Cambridge Commonwealth Trust Fellowship, which he used to complete his PhD at the University of Cambridge. During his PhD, he described a novel signaling pathway involving nuclear JAK2 as a chromatin-modifying enzyme. Following his PhD, he was awarded the inaugural Wellcome Trust Beit Prize Fellowship to pursue his research into epigenetic regulation of leukaemia stem cells. This research also conducted at the University of Cambridge, identified a novel therapeutic strategy for acute myeloid leukaemia by targeting the BET bromodomain proteins that function as epigenetic readers. Associate Professor Dawson moved to the Peter MacCallum Cancer centre in 2014 and is currently the Senior Fellow for the Leukaemia Foundation Australia, He is also a VESKI Innovation Fellow and The Herman Clinical Fellow at the University of Melbourne.